Fromtling RA, et al. Decreased virulence in stable, acapsular mutants of cryptococcus neoformans. Mycopathologia 79: 23-29, 1982. PubMed: 6750405
Jacobson ES, Payne WR. UDP glucuronate decarboxylase and synthesis of capsular polysaccharide in Cryptococcus neoformans. J. Bacteriol. 152: 932-934, 1982. PubMed: 6752126
Still CN, Jacobson ES. Recombinational mapping of capsule mutations in Cryptococcus neoformans. J. Bacteriol. 156: 460-462, 1983. PubMed: 6352689
Jacobson ES, et al. Genetic and phenotypic characterization of capsule mutants of Cryptococcus neoformans. J. Bacteriol. 150: 1292-1296, 1982. PubMed: 7042689
Nosanchuk JD, et al. Amphotericin B and fluconazole affect cellular charge, macrophage phagocytosis, and cellular morphology of Cryptococcus neoformans at subinhibitory concentrations. Antimicrob. Agents Chemother. 43: 233-239, 1999. PubMed: 9925511
Mody CH, et al. The cell wall and membrane of Cryptococcus neoformans possess a mitogen for human T lymphocytes. Infect. Immun. 67: 936-941, 1999. PubMed: 9916111
Pietrella D, et al. Cytotoxic T lymphocyte antigen costimulation influences T-cell activation in response to Cryptococcus neoformans. Infect. Immun. 69: 1508-1514, 2001. PubMed: 11179320
acapsular mutant of NIH B-3501
|
